These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 27500820)
1. The impact of cognitive challenges in major depression: the role of the primary care physician. Mattingly G; Anderson RH; Mattingly SG; Anderson EQ Postgrad Med; 2016 Sep; 128(7):665-71. PubMed ID: 27500820 [TBL] [Abstract][Full Text] [Related]
2. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Baune BT; Brignone M; Larsen KG Int J Neuropsychopharmacol; 2018 Feb; 21(2):97-107. PubMed ID: 29053849 [TBL] [Abstract][Full Text] [Related]
3. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Smith J; Browning M; Conen S; Smallman R; Buchbjerg J; Larsen KG; Olsen CK; Christensen SR; Dawson GR; Deakin JF; Hawkins P; Morris R; Goodwin G; Harmer CJ Mol Psychiatry; 2018 May; 23(5):1127-1133. PubMed ID: 28533517 [TBL] [Abstract][Full Text] [Related]
4. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city]. Mouchabac S; Ferreri M; Cabanac F; Bitton M Encephale; 2003; 29(5):438-44. PubMed ID: 14615693 [TBL] [Abstract][Full Text] [Related]
5. Cognitive control, reward-related decision making and outcomes of late-life depression treated with an antidepressant. Alexopoulos GS; Manning K; Kanellopoulos D; McGovern A; Seirup JK; Banerjee S; Gunning F Psychol Med; 2015 Oct; 45(14):3111-20. PubMed ID: 26169527 [TBL] [Abstract][Full Text] [Related]
6. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Levada OA; Troyan AS J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363 [TBL] [Abstract][Full Text] [Related]
7. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Frampton JE Drugs; 2016 Nov; 76(17):1675-1682. PubMed ID: 27807822 [TBL] [Abstract][Full Text] [Related]
8. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419 [TBL] [Abstract][Full Text] [Related]
10. Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD study. Greer TL; Grannemann BD; Chansard M; Karim AI; Trivedi MH Eur Neuropsychopharmacol; 2015 Feb; 25(2):248-56. PubMed ID: 25453481 [TBL] [Abstract][Full Text] [Related]
11. Cognitive remission: a novel objective for the treatment of major depression? Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406 [TBL] [Abstract][Full Text] [Related]
12. [Cognitive impairments in patients with depression]. Schilling TM; Bossert M; Weisbrod M; Aschenbrenner S Nervenarzt; 2021 Mar; 92(3):277-288. PubMed ID: 33646323 [TBL] [Abstract][Full Text] [Related]
13. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Freeman MP; Cheng LJ; Moustafa D; Davies A; Sosinsky AZ; Wang B; Petrillo LF; Hogan C; Cohen LS Ann Clin Psychiatry; 2017 Nov; 29(4):249-257. PubMed ID: 29069110 [TBL] [Abstract][Full Text] [Related]
14. Sexual dysfunction associated with major depressive disorder and antidepressant treatment. Clayton AH; El Haddad S; Iluonakhamhe JP; Ponce Martinez C; Schuck AE Expert Opin Drug Saf; 2014 Oct; 13(10):1361-74. PubMed ID: 25148932 [TBL] [Abstract][Full Text] [Related]
16. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression. Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049 [TBL] [Abstract][Full Text] [Related]
18. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955 [TBL] [Abstract][Full Text] [Related]
19. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder. Sumiyoshi T; Hoshino T; Mishiro I; Hammer-Helmich L; Ge H; Moriguchi Y; Fujikawa K; Fernandez JL J Affect Disord; 2022 Jan; 296():95-102. PubMed ID: 34597893 [TBL] [Abstract][Full Text] [Related]
20. The screen for cognitive impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major depression. Tourjman SV; Juster RP; Purdon S; Stip E; Kouassi E; Potvin S Int J Psychiatry Clin Pract; 2019 Mar; 23(1):49-56. PubMed ID: 29553848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]